MarketInOut Stock Screener Log In | Sign Up

Enlivex Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Enlivex Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.83 mln
Float1.53 mln
Earnings Date04/23/2027

EPS

7,904
Exceptional

P / E

0.00
Anomalous

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

1,280.00
Transformational upside

Relative Strength

1 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

Business Description

Enlivex is an Israeli biotech company founded in 2005 and based in Ness Ziona, focused on developing a cell-based therapy called Allocetra that works by retraining the immune system's macrophage cells to behave normally. The company is currently running clinical trials to test Allocetra across several serious medical conditions, including knee and jaw joint deterioration, as well as life-threatening organ failure caused by sepsis. Its work sits at an early but promising stage, with multiple studies underway to establish the safety and effectiveness of its approach.

Key Fundamentals

EPS7,904
P/E0.00
ROE213
ROIC-0.54
ROA172
Interest Cover-15.46
EBITDA, mln4,083
EV / EBITDA0.02
EV / EBIT0.02

Quote Details

Last 1.78
Change -0.76 (-29.92%)
Open 2.47
Volume 127,867
Turnover 227,603
Average Volume 148,506

Financial Ratios

Leverage Ratio1.26
Current Ratio119
Price / Book0.01
Price / Tangible Book0.02
Debt / Equity0.01

Financial Strength

Piotroski F-Score 4 / 9
Price to Intrinsic Value0.02
Price to Graham Number0.02
1-Year Target Price1,280.00
Short Ratio0.07
Short % of Float0.80

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -35.74% 1 / 100   
1 Month -73.67% 1 / 100   
2 Months -97.39% 0 / 100   
6 Months -99.09% 1 / 100   
1 Year -99.31% 1 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog